Toll-Like Receptors and COVID-19: A Two-Faced Story with an Exciting Ending
2020; Future Science Ltd; Volume: 6; Issue: 8 Linguagem: Inglês
10.2144/fsoa-2020-0091
ISSN2056-5623
AutoresLivia Onofrio, Michele Caraglia, Gaetano Facchini, Vincenzo Margherita, Sabino De Placido, Carlo Buonerba,
Tópico(s)Phagocytosis and Immune Regulation
ResumoFuture Science OAVol. 6, No. 8 EditorialOpen AccessToll-like receptors and COVID-19: a two-faced story with an exciting endingLivia Onofrio, Michele Caraglia, Gaetano Facchini, Vincenzo Margherita, Sabino De Placido & Carlo BuonerbaLivia OnofrioDepartment of Clinical Medicine & Surgery, University of Naples "Federico II", Naples, Italy, Michele CaragliaDepartment of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy, Gaetano FacchiniMedical Oncology, ASL Napoli 2 Nord, "S.M. delle Grazie Hospital", Pozzuoli (NA), Italy, Vincenzo MargheritaDepartment of Clinical Medicine & Surgery, University of Naples "Federico II", Naples, Italy, Sabino De PlacidoDepartment of Clinical Medicine & Surgery, University of Naples "Federico II", Naples, Italy & Carlo Buonerba*Author for correspondence: E-mail Address: carlo.buonerba@izsmportici.itRegional Reference Center for Rare Tumors, Department of Oncology & Hematology, AOU Federico II of Naples, Naples, ItalyNational Reference Center for Environmental Health, Zoo-prophylactic Institute of Southern Italy, Portici, ItalyPublished Online:30 Jul 2020https://doi.org/10.2144/fsoa-2020-0091AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit Coronavirus disease 19 (COVID-19) is caused by a novel single-stranded RNA beta-coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 has quickly become a pandemic since the first case was diagnosed in Wuhan, China, in December 2019, with currently over 5 million people infected and over 340,000 deaths in more than 200 different countries [2]. SARS-CoV-2 molecular structure presents four major proteins named the spike (S), envelope (E), membrane (M) and nucleocapsid (N). Approximately 80% of SARS-CoV-2 genomic sequence is in common with SARS-CoV, the virus responsible for the SARS outbreak in 2002 [3]. Despite close similarities, the SARS-CoV-2 Spike protein – which allows the virus to bind to the ACE2 receptor – is several amino acids longer than the SARS-CoV Spike protein, which may represent the key reason why COVID-19 has spread so rapidly throughout the world, inherently different from SARS, which was quickly contained [3].From a clinical point of view, SARS-CoV-2 infection is highly heterogeneous. In a report including over 40 thousand cases diagnosed in China [4], mild disease was reported in approximately 80% of patients, severe signs or symptoms including dyspnea, hypoxia or lung infiltrates involving >50% of the parenchyma occurred in 14% of patients, while signs indicative of critical disease such as shock, respiratory failure or multiorgan dysfunction were reported in 5% of cases. Of note, mortality was 2.3% in the entire cohort. With such a highly heterogeneous clinical course, SARS-CoV-2 infection poses a challenge for researchers to define its underlying biological mechanisms as well as for clinicians to establish the optimal therapeutic approach, which remains elusive at the present time.While most patients infected with SARS-CoV-2 remain asymptomatic or show mild disease, the clinical course in those who develop severe COVID-19 includes onset of dyspnea after 5–6 days, necessity of hospitalization after 7–8 days and development of acute respiratory distress syndrome (ARDS) after approximately 8–12 days from onset of symptoms [5]. Mortality in patients admitted to the intensive care unit can be as high as 60% [6]. Current therapeutic management of patients with severe COVID-19 is primarily based on ventilation support, with a potential role played by a few pharmacological agents. Remdesivir, a nucleotide analog with in vitro evidence of anti-SARS-CoV-2 activity, has shown encouraging activity against severe COVID-19. Remdesivir versus placebo was associated with an improvement in time to recovery in a preliminary report involving 1063 randomized COVID-19 patients with severe respiratory disease, although mortality remained high in both arms (mortality at 14 days: 7.1 vs 11.9% with remdesivir vs placebo, hazard ratio for death, 0.70; 95% CI: 0.47–1.04) [7]. Another retrospective study reported about 20 patients with severe COVID-19 treated with tocilizumab, a monoclonal antibody directed against IL-6, a key player in the so-called 'cytokine storm' associated with COVID-19 ARDS. With 15 patients being able to decrease their oxygen intake, one being able to breath in ambient air, and no reported deaths, tocilizumab demonstrated some efficacy [8]. Results from a large prospective trial with tocilizumab [9] are pending. Although other pharmacological agents have been proposed or tested, including azithromycin, recombinant soluble ACE2, lopinavir/ritonavir [10] as well as eculizumab [11], effective pharmacological agents against such a deadly disease remain a compelling need at the present time.Toll-like receptors (TLRs) [12] may be involved both in the initial failure of viral clearance and in the subsequent development of the deadly clinical manifestations of severe COVID-19 – essentially ARDS with fatal respiratory failure. TLRs are ubiquitously present in the animal kingdom. In humans, the TLR family comprises ten members (TLR1–TLR10), which are expressed in innate immune cells such as macrophages as well as in epithelial and fibroblast cells. Activation of TLRs can be induced by a multitude of pathogen-associated molecular patterns (PAMPs) present in bacteria, viruses and other foreign organisms. TLRs play a major role in the initiation of innate immune responses, with the production of inflammatory cytokines, type I IFN and other mediators. TLRs can be localized either on the cell surface, such as TLR-1, -2, -4, -5, -6, -10 or in the endosome compartment, such as TLR-3, -7, -8, -9 [12]. Importantly, while TLR3 recognizes viral double-stranded RNA (dsRNA), TLR7 recognizes viral single-stranded RNA and is therefore, likely to be implicated in clearance of SARS-CoV-2 [13]. TLR activation via MyD88-dependent and TRIF-dependent pathways causes nuclear translocation of the transcription factors NF-κB, IRF-3 and IRF-7, with production of innate pro-inflammatory cytokines (IL-1, IL-6, TNF-α) and type I IFN-α/β, which are essential for anti-viral responses [13]. Similarly to SARS-CoV, SARS-CoV-2 may prevent a successful immune response in infected individuals who progress to severe COVID-19 via inhibition of the TNF-receptor-associated factors (TRAF) -3 and -6, which play an essential role in inducing IRF-3/7 in response to TLR-7 activation. Available agonists against TLR-7 may prevent onset of severe COVID-19 in symptomatic patients and synergize with active anti-viral therapy.In experimental mouse models of ARDS induced by multiple noxae, including SARS-CoV, genetic inactivation of the TLR-4 gene, but not of TLR-3 or 9 genes, was associated with reduced acute lung injury [14]. An improvement was also noted in IL-6-/- mice, which is consistent with the promising results obtained with tocilizumab. In patients with severe COVID-19, lung macrophages may play a key role in the massive release of IL-6 and other cytokines, including TNF-α, IL-1β, IL-10 and IL-12 via TLRs activation [15]. Of note, in an in vitro model, stimulation of human lung macrophages with subtype-selective agonists against various TLRs demonstrated that TLR4 stimulation induced the strongest effect in terms of cytokine release. Although SARS-CoV-2 is unlikely to activate TLR-4 directly, as TLR-4 responds to bacteria [12], one hypothesis based on a mouse model of acute lung injury is that oxidized phospholipids can be responsible for activation of TLR-4 and onset of ARDS [14]. It is interesting to note that neutrophil myeloperoxidase, which is reported to be at increased levels in COVID-19 patients, especially in those on ventilation support [16], is capable to oxidase phospholipids [17] abundant in alveolar surfactant [18]. TLR-4 may, therefore, represent a druggable target against COVID-19 via the use of TLR-4 antagonists.Major difficulties in identifying effective therapeutic options in patients with severe COVID-19 lie in the heterogeneity of the disease and its erratic course, with some patients with mild symptoms at presentation developing sudden respiratory failure. On 1 May 2020, remdesivir was authorized by the FDA, MA, USA for treatment of severe COVID-19 requiring hospitalization, on the grounds of data obtained with the NIAID [7] and the Gilead-sponsored [19] trials. These trials enrolled hospitalized patients with different levels of respiratory insufficiency, including patients not requiring supplemental oxygen with an SpO2 <94% and those requiring mechanical ventilation, but it is currently unknown whether remdesivir efficacy may vary according to severity of the disease. Pending full analysis of remdesivir efficacy data, which should disclosure whether there are subgroup of patients who benefit less from treatment (e.g., those with more severe disease), we hypothesize that remdesivir may synergize with pharmacological agonists against TLR-7, which may be involved in viral escape mechanisms from immune clearance, as discussed above. In simian-human immunodeficiency virus (SHIV)-SF162P3-infected rhesus monkeys, administration of the TLR7 agonist vesatolimod during anti-retroviral therapy (ART) was associated with a delayed viral rebound after ART suspension [20]. In a Phase II trial conducted in 162 patients with hepatitis B, vesatolimod demonstrated remarkable safety in combination antiviral treatment, with signs of biological activity determined by an increase in IFN-stimulated gene mRNA expression [21]. Vesatolimod has been shown to be safe and biologically active and may be tested in COVID-19 in combination with active anti-viral therapy. Conversely, TLR-4 antagonists may be useful in patients on respiratory support with ARDS, possibly in combination with anti-IL-6 agents. Eritoran is a well-tolerated TLR4 antagonist that was tested for the treatment of severe sepsis in a large randomized controlled clinical trial, where it exhibited an excellent safety profile, although it yielded no improvement in mortality [22]. In an influenza mouse model, Eritoran was able to improve clinical symptoms and pathologic lung damage, while decreasing oxidized phospholipid and cytokine levels, as well as mortality [23].Clinical testing of TLR agonists/antagonists may be optimized on the grounds of the following three key points. First, even patients with severe COVID-19 demonstrate a time-dependent spectrum of clinical manifestations, ranging from desaturation with no oxygen supplementation required to need of mechanical ventilation. We hypothesize that patients with less severe disease may more likely benefit from early anti-viral therapy, possibly in combination with TLR-7 agonists. Conversely, patients on mechanical ventilation suffering from ARDS may benefit from anti-IL-6 treatment, possibly in combination with TLR-4 antagonists. Second, intermediate biological markers of therapy efficacy that may also be useful in clinical practice represent a powerful tool to explore efficacy of multiple TLR-modulating agents. Signs of efficacy of TLR-7 agonists in combination with anti-viral therapy may be captured by an early drop in viral load, while decreasing IL-6 levels may capture efficacy of TLR-4 antagonists even in small patient populations. Third, the target population may include mildly symptomatic patients positive to SARS-CoV-2 with known risk factors for COVID-19 mortality, such as age and comorbidities, who may benefit from early treatment before onset of severe COVID-19.In the current scenario in which only few therapeutic options against COVID-19 are available, targeting TLRs using pharmacological agents ready for clinical testing may provide major therapeutic advances in the fight against this deadly disease, which is unlikely to be eradicated for the next decades.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/References1. Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382(8), 727–733 (2020).Crossref, CAS, Google Scholar2. WHO (2019). www.who.int/emergencies/diseases/novel-coronavirus-2019Google Scholar3. Rabaan AA, Al-Ahmed SH, Haque S et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Le Infez. Med. 28(2), 174–184 (2020).CAS, Google Scholar4. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA – J. Am. Med. Assoc. 323(13), 1239–1242 (2020).Crossref, CAS, Google Scholar5. Cevik M, Bamford C, Ho A. COVID-19 pandemic – a focused review for clinicians. Clin. Microbiol. Infect. S1198-743X(20)30231-7 (2020). https://pubmed.ncbi.nlm.nih.gov/32344166Crossref, Google Scholar6. Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8(5), 475–481 (2020).Crossref, CAS, Google Scholar7. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the treatment of Covid-19 – preliminary report. N. Engl. J. Med. (2020) (Epub ahead of print).Crossref, Google Scholar8. Xu X, Han M, Li T et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc/ Natl Acad. Sci. USA 117(20), 10970–10975 (2020).Crossref, CAS, Google Scholar9. Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19) (2020). https://clinicaltrials.gov/ct2/show/NCT04317092Google Scholar10. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. Clin. Immunol. 215, 108448 (2020).Crossref, CAS, Google Scholar11. Diurno F, Numis FG, Porta G et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur. Rev. Med. Pharmacol. Sci. 24(7), 4040–4047 (2020).CAS, Google Scholar12. O'Neill LAJ, Golenbock D, Bowie AG. The history of Toll-like receptors-redefining innate immunity. Nat. Rev. Immunol. 13(6), 453–460 (2013).Crossref, Google Scholar13. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front. Immunol. 5(SEP), 461 (2014).Google Scholar14. Imai Y, Kuba K, Neely GG et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133(2), 235–249 (2008).Crossref, CAS, Google Scholar15. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 19(6), 102537 (2020).Crossref, CAS, Google Scholar16. Zuo Y, Yalavarthi S, Shi H et al. Neutrophil extracellular traps in COVID-19. JCI Insight 27(191), 26–27 (2020).Google Scholar17. Crouch EC, Hirche TO, Shao B et al. Myeloperoxidase-dependent inactivation of surfactant protein D in vitro and in vivo. J. Biol. Chem. 285(22), 16757–16770 (2010).Crossref, CAS, Google Scholar18. Agassandian M, Mallampalli RK. Surfactant phospholipid metabolism. Biochim. Biophys. Acta – Mol. Cell Biol. Lipids 1831(3), 612–625 (2013).Crossref, CAS, Google Scholar19. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) (2020). https://clinicaltrials.gov/ct2/show/NCT04292899Google Scholar20. Borducchi EN, Liu J, Nkolola JP et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563(7731), 360–364 (2018).Crossref, CAS, Google Scholar21. Janssen HLA, Brunetto MR, Kim YJ et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J. Hepatol. 68(3), 431–440 (2018).Crossref, CAS, Google Scholar22. Opal SM, Laterre PF, Francois B et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA – J. Am. Med. Assoc. 309(11), 1154–1162 (2013).Crossref, CAS, Google Scholar23. Shirey KA, Lai W, Scott AJ et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497(7450), 498–502 (2013).Crossref, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByAssociation of COVID-19 with Comorbidities: An Update27 February 2023 | ACS Pharmacology & Translational Science, Vol. 6, No. 3Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID22 February 2023 | Cells, Vol. 12, No. 5Solanum nigrum L. in COVID-19 and post-COVID complications: a propitious candidate23 January 2023 | Molecular and Cellular Biochemistry, Vol. 27In-Silico Designing of a Multi-Epitope Vaccine against SARS-CoV2 and Studying the Interaction of the Vaccine with Alpha, Beta, Delta and Omicron Variants of ConcernCurrent Drug Discovery Technologies, Vol. 20, No. 1COVID-19 Pnömonisi ile Yoğun Bakıma Yatan Hastalarda Yüksek Akışlı Nazal Oksijen Tedavisinin Etkinliğinin Retrospektif Olarak Değerlendirilmesi2 December 2022 | Black Sea Journal of Health ScienceAlterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions29 April 2022 | Signal Transduction and Targeted Therapy, Vol. 7, No. 1Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities1 December 2022 | International Journal of Molecular Sciences, Vol. 23, No. 23Review on the role of host genetic factors in the susceptibility to SARS-CoV-21 December 2022 | MEDICAL SCIENCES JOURNAL, Vol. 32, No. 4Targeting TLR-4 Signaling to Treat COVID-19-induced Acute Kidney Injury31 January 2023 | Journal of Pharmacology and Pharmacotherapeutics, Vol. 13, No. 4Macrophage Boolean networks in the time of SARS-CoV-217 October 2022 | Frontiers in Immunology, Vol. 13Long-COVID in immunocompromised children14 July 2022 | European Journal of Pediatrics, Vol. 181, No. 9Individual genetic variability mainly of Proinflammatory cytokines, cytokine receptors, and toll‐like receptors dictates pathophysiology of COVID‐19 disease31 May 2022 | Journal of Medical Virology, Vol. 94, No. 9Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions1 August 2022 | MedComm, Vol. 3, No. 3Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach14 September 2022 | International Journal of Molecular Sciences, Vol. 23, No. 18Chronic Mild Stress and COVID-19 Sequelae1 September 2022Natural killer cell exhaustion in SARS-CoV-2 infection22 June 2022 | Innate Immunity, Vol. 28, No. 6Synthesis of imidazolocoumarins by the amide-directed oxidative cyclisation of enol-Ugi derivatives1 January 2022 | Organic & Biomolecular Chemistry, Vol. 20, No. 26Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review22 February 2022 | Immunologic Research, Vol. 70, No. 3Nanostructures for the Prevention, Diagnosis, and Treatment of SARS-CoV-2: A Review28 February 2022 | ACS Applied Nano Materials, Vol. 5, No. 5Nanotechnology-based therapeutics for targeting inflammatory lung diseasesNanomedicine, Vol. 17, No. 12All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study12 October 2021 | Internal and Emergency Medicine, Vol. 17, No. 3SARS-CoV-2 interacts with renin-angiotensin system: impact on the central nervous system in elderly patients14 February 2022 | GeroScience, Vol. 44, No. 2COVID-19 in children: acute endotheliopathy, but forgotten prostacyclin replacement?21 June 2021 | Cardiology in the Young, Vol. 32, No. 4COVID-19 and its impact on the brain and Mind- A conceptual model and supporting evidence18 March 2022 | Psychiatric Quarterly, Vol. 93, No. 1Role of toll‐like receptors in modulation of cytokine storm signaling in SARS‐CoV‐2‐induced COVID‐1926 October 2021 | Journal of Medical Virology, Vol. 94, No. 3Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?13 January 2022 | Molecular Neurobiology, Vol. 59, No. 3Thrombosis and fibrosis: mutually inclusive targets to combat in COVID-19Mehmet Agirbasli17 December 2021 | Future Science OA, Vol. 8, No. 2The Promising Mechanisms of Low Molecular Weight Compounds of Panax Ginseng C.A. Meyer in Alleviating COVID-19: A Network Pharmacology Analysis9 February 2022 | Processes, Vol. 10, No. 2Deciphering Respiratory-Virus-Associated Interferon Signaling in COPD Airway Epithelium13 January 2022 | Medicina, Vol. 58, No. 1Daphnoretin from Carthamus tinctorius as a Potential Inflammatory Inhibitor in COVID-19 by Binding to Toll-like Receptor-4: An in silico Molecular Docking Study31 January 2022 | Open Access Macedonian Journal of Medical Sciences, Vol. 10, No. AFrontiers in Microbiology, Vol. 13Potential immunological effects of gender-affirming hormone therapy in transgender people – an unexplored area of research10 December 2022 | Therapeutic Advances in Endocrinology and Metabolism, Vol. 13COVID-19 infection and neurodegeneration: Computational evidence for interactions between the SARS-CoV-2 spike protein and monoamine oxidase enzymesComputational and Structural Biotechnology Journal, Vol. 20Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients16 December 2021 | Frontiers in Aging, Vol. 2The intersection of COVID-19 and cancer: signaling pathways and treatment implications17 May 2021 | Molecular Cancer, Vol. 20, No. 1Vitamin D Endocrine System and COVID‐1917 November 2021 | JBMR Plus, Vol. 5, No. 12Host factors: Implications in immunopathogenesis of COVID-19Pathology - Research and Practice, Vol. 228A reverse vaccinology and immunoinformatics approach for designing a multiepitope vaccine against SARS-CoV-220 September 2021 | Immunogenetics, Vol. 73, No. 6Designing of a Multi-epitope Vaccine against the Structural Proteins of Marburg Virus Exploiting the Immunoinformatics Approach18 November 2021 | ACS Omega, Vol. 6, No. 47Aging Immune System and Its Correlation With Liability to Severe Lung Complications23 November 2021 | Frontiers in Public Health, Vol. 9Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-1911 November 2021 | Frontiers in Immunology, Vol. 12Histomorphological patterns of regional lymph nodes in COVID-19 lungs5 May 2021 | Der Pathologe, Vol. 42, No. S1Macrophage Activation Syndrome and COVID 19: Impact of MAPK Driven Immune-Epigenetic Programming by SARS-Cov-21 October 2021 | Frontiers in Immunology, Vol. 12COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment – A narrative reviewBest Practice & Research Clinical Anaesthesiology, Vol. 35, No. 3Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation?14 September 2021 | Frontiers in Cell and Developmental Biology, Vol. 9TRINITY OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2: ORIGIN, GENOTYPE, PHENOTYPE, AND IMMUNE RESPONSE IN CORONAVIRUS DISEASE-20196 September 2021 | Asian Journal of Pharmaceutical and Clinical ResearchSARS-CoV-2 and its beta variant of concern infect human conjunctival epithelial cells and induce differential antiviral innate immune responseThe Ocular Surface, Vol. 382SARS-CoV-2, COVID-19 and the aging immune system14 September 2021 | Nature Aging, Vol. 1, No. 9Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infectionJournal of Biological Chemistry, Vol. 297, No. 2Promising role of curcumin against viral diseases emphasizing COVID-19 management: A review on the mechanistic insights with reference to host-pathogen interaction and immunomodulationJournal of Functional Foods, Vol. 82Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 PathogenesisClinical Microbiology Reviews, Vol. 34, No. 3Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinson's Disease15 June 2021 | Frontiers in Cellular Neuroscience, Vol. 15The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entityThe Lancet Respiratory Medicine, Vol. 9, No. 6Role of Toll‐like receptors in the pathogenesis of COVID‐199 February 2021 | Journal of Medical Virology, Vol. 93, No. 5Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management17 May 2021 | Biomedicines, Vol. 9, No. 5In silico analyses on the comparative sensing of SARS‐CoV‐2 mRNA by the intracellular TLRs of humans12 January 2021 | Journal of Medical Virology, Vol. 93, No. 4Nanotechnology to the Rescue: Treatment Perspective for the Immune Dysregulation Observed in COVID-1931 March 2021 | Frontiers in Nanotechnology, Vol. 3Reaktionsmuster der lokoregionären Lymphknoten im Abflussgebiet von COVID-19-Lungen11 February 2021 | Der Pathologe, Vol. 42, No. 2A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review26 February 2021 | Frontiers in Pharmacology, Vol. 11Journey to a Receptor for Advanced Glycation End Products Connection in Severe Acute Respiratory Syndrome Coronavirus 2 InfectionArteriosclerosis, Thrombosis, and Vascular Biology, Vol. 41, No. 2Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?12 January 2021 | Frontiers in Physiology, Vol. 11The use of chest ultrasonography in suspected cases of COVID-19 in the emergency departmentEnrico Allegorico, Carlo Buonerba, Giorgio Bosso, Antonio Pagano, Giovanni Porta, Claudia Serra, Pasquale Dolce, Valentina Minerva, Ferdinando Dello Vicario, Concetta Altruda, Paola Arbo, Teresa Russo, Chiara De Sio, Nicoletta Franco, Gianluca Ruffa, Cinzia Mormile, Francesca Cannavacciuolo, Valentina Mercurio, Gelsomina Gervasio, Giuseppe Di Costanzo, Alfonso Ragozzino, Luca Scafuri, Gaetano Facchini & Fabio Numis1 December 2020 | Future Science OA, Vol. 7, No. 1Welcome to volume 7 of Future Science OAFrancesca Lake18 December 2020 | Future Science OA, Vol. 7, No. 1Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches1 March 2021 | ImmunoTargets and Therapy, Vol. Volume 10Comparison of the Characteristics of Cytokine Storm and Immune Response Induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections1 October 2021 | Journal of Inflammation Research, Vol. Volume 14Toll-Like Receptor 4 Polymorphisms (896A/G and 1196C/T) as an Indicator of COVID-19 Severity in a Convenience Sample of Egyptian Patients1 November 2021 | Journal of Inflammation Research, Vol. Volume 14Gender and genetic factors impacting COVID-19 severityJournal of Family Medicine and Primary Care, Vol. 10, No. 11Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19Current Research in Pharmacology and Drug Discovery, Vol. 2A case report of monoarthritis in a COVID-19 patient and literature review11 June 2021 | Medicine, Vol. 100, No. 23Association between ABO blood groups and susceptibility to COVID-19: profile of age and gender in Iraqi patients17 December 2020 | Egyptian Journal of Medical Human Genetics, Vol. 21, No. 1SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19Food and Chemical Toxicology, Vol. 146ROLE OF TOLL-LIKE RECEPTORS IN CORONAVIRUS INFECTION AND IMMUNE RESPONSE25 October 2020 | Journal of Experimental Biology and Agricultural Sciences, Vol. 8, No. Spl-1-SARS-CoV-2 Vol. 6, No. 8 Follow us on social media for the latest updates Metrics History Received 23 May 2020 Accepted 28 May 2020 Published online 30 July 2020 Published in print September 2020 Information© 2020 Carlo BuonerbaFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/PDF download
Referência(s)